Literature DB >> 15544030

Growth factor activation in myocardial vascularization: therapeutic implications.

Robert J Tomanek1, Wei Zheng, Xinping Yue.   

Abstract

A rapid growth of the coronary vasculature occurs during prenatal and early postnatal periods as precursor cells from the epi- and sub-epicardium differentiate, migrate and form vascular structures (vasculogenesis) which then fuse, branch and in some cases recruit cells to form three tunics (angiogenesis). These processes are tightly controlled by temporally and spatially expressed growth factors which are stimulated by metabolic and mechanical factors. The process of angiogenesis in the myocardium is not limited to developmental periods of life, but may occur when the heart is challenged by enhanced loading conditions or during hypoxia or ischemia. This review focuses on the activation of growth factors by metabolic and mechanical stimuli in the developing heart and in the adult heart undergoing adaptive responses. Experimental studies support the hypotheses that both metabolic (hypoxia) and mechanical (stretch) factors serve as powerful stimuli for the up-regulation of growth factors which facilitate angiogenesis and arteriogenesis. Both hypoxia and stretch are powerful inducers of VEGF and its receptors, and provide for paracrine and autocrine signaling. In addition to the VEGF family, bFGF and angiopoietins play major roles in myocardial vascularization. Sufficient evidence supports the hypothesis that mechanical (e.g., bradycardia) and metabolic (e.g., thyroxine analogs) may provide effective non-invasive angiogenic therapies for the ischemic and post-infarcted heart.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544030     DOI: 10.1023/b:mcbi.0000044369.88528.a3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  76 in total

Review 1.  Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease.

Authors:  N van Royen; J J Piek; I Buschmann; I Hoefer; M Voskuil; W Schaper
Journal:  Cardiovasc Res       Date:  2001-02-16       Impact factor: 10.787

Review 2.  Delivery strategies to achieve therapeutic myocardial angiogenesis.

Authors:  R Kornowski; S Fuchs; M B Leon; S E Epstein
Journal:  Circulation       Date:  2000-02-01       Impact factor: 29.690

3.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.

Authors:  D W Losordo; P R Vale; J F Symes; C H Dunnington; D D Esakof; M Maysky; A B Ashare; K Lathi; J M Isner
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

Review 4.  Exercise-induced coronary angiogenesis: a review.

Authors:  R J Tomanek
Journal:  Med Sci Sports Exerc       Date:  1994-10       Impact factor: 5.411

5.  Coronary vascularization during development in the rat and its relationship to basic fibroblast growth factor.

Authors:  R J Tomanek; L Haung; P R Suvarna; L C O'Brien; A Ratajska; A Sandra
Journal:  Cardiovasc Res       Date:  1996-02       Impact factor: 10.787

6.  Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia.

Authors:  A Lymboussaki; B Olofsson; U Eriksson; K Alitalo
Journal:  Circ Res       Date:  1999-11-26       Impact factor: 17.367

Review 7.  Gene therapy in vascular medicine: recent advances and future perspectives.

Authors:  R Morishita; M Aoki; Y Kaneda; T Ogihara
Journal:  Pharmacol Ther       Date:  2001-08       Impact factor: 12.310

8.  Capillary growth and changes in heart performance induced by chronic bradycardial pacing in the rabbit.

Authors:  A J Wright; O Hudlicka
Journal:  Circ Res       Date:  1981-08       Impact factor: 17.367

9.  Functional and morphological characteristics of compensated and decompensated cardiac hypertrophy in dogs with chronic infrarenal aorto-caval fistulas.

Authors:  F Legault; J L Rouleau; C Juneau; C Rose; K Rakusan
Journal:  Circ Res       Date:  1990-03       Impact factor: 17.367

Review 10.  Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders.

Authors:  Aernout Luttun; Marc Tjwa; Peter Carmeliet
Journal:  Ann N Y Acad Sci       Date:  2002-12       Impact factor: 5.691

View more
  3 in total

1.  Bioengineering the infarcted heart by applying bio-inspired materials.

Authors:  Emil Ruvinov; Tamar Harel-Adar; Smadar Cohen
Journal:  J Cardiovasc Transl Res       Date:  2011-06-08       Impact factor: 4.132

2.  Combining neuropeptide Y and mesenchymal stem cells reverses remodeling after myocardial infarction.

Authors:  Yigang Wang; Dongsheng Zhang; Muhammad Ashraf; Tiemin Zhao; Wei Huang; Atif Ashraf; Ambikaipakan Balasubramaniam
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-11-06       Impact factor: 4.733

3.  The anti-angiogenic factor PEDF is present in the human heart and is regulated by anoxia in cardiac myocytes and fibroblasts.

Authors:  Kathrin Rychli; Christoph Kaun; Philipp J Hohensinner; Adrian J Dorfner; Stefan Pfaffenberger; Alexander Niessner; Michael Bauer; Wolfgang Dietl; Bruno K Podesser; Gerald Maurer; Kurt Huber; Johann Wojta
Journal:  J Cell Mol Med       Date:  2010-01       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.